Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study
机构：[1]Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[3]Zhongshan Hospital, Fudan University, Shanghai, China[4]Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China, Haerbin, China[5]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[6]Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China中山大学附属第一医院[7]Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China[8]Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China[9]Breast Cancer Center, Tianjin, China[10]Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[11]Department of Breast Surgery, Shanghai Ruijin Hospital, Shanghai, China[12]The First People's Hospital of Foshan, Foshan, China[13]Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China[14]Sun Yat-sen University Cancer Center, Guangzhou, China[15]Tangshan People's Hospital, Tangshan, China[16]the Affiliated Hospital of Hebei University, Baoding, China河北大学附属医院[17]Department of Tumor Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China[18]Department of Breast Surgery, Shandong Provincial Cancer Hospital, Jinan, China[19]Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China[20]Fudan University Shanghai Cancer Center, Shanghai, China
第一作者机构：[1]Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China[3]Zhongshan Hospital, Fudan University, Shanghai, China[4]Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China, Haerbin, China[5]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China[6]Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China[7]Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China[8]Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China[9]Breast Cancer Center, Tianjin, China[10]Zhejiang Cancer Hospital, Hangzhou, China[11]Department of Breast Surgery, Shanghai Ruijin Hospital, Shanghai, China[12]The First People's Hospital of Foshan, Foshan, China[13]Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China[14]Sun Yat-sen University Cancer Center, Guangzhou, China[15]Tangshan People's Hospital, Tangshan, China[16]the Affiliated Hospital of Hebei University, Baoding, China[17]Department of Tumor Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China[18]Department of Breast Surgery, Shandong Provincial Cancer Hospital, Jinan, China[19]Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China[20]Fudan University Shanghai Cancer Center, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhao Yannan,Geng Cuizhi,Zhang Hongwei,et al.Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Zhao, Yannan,Geng, Cuizhi,Zhang, Hongwei,Cai, Li,Yao, Herui...&Hu, Xichun.(2023).Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Zhao, Yannan,et al."Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学